Novavax's Shot Effective Against Covid in Final Trial Analysis
John Lauerman
3/12/2021 12:26:07 PM
This article was written by John Lauerman in Bloomberg:
Novavax Inc.'s Covid-19 vaccine was 96.4% effective against mild, moderate and severe symptoms of the disease in the final analysis of a late-stage trial in the U.K.
Shares of the drugmaker were up 16% in after-hours trading Thursday in New York. Since the start of this year, the stock had gained more than 68% through Thursday's close.
The company also released final results of a mid-stage trial from South Africa showing that its vaccine was 55.4% effective against a variant circulating there that's already been shown to partially elude the effects of some shots. Both studies reached their statistical goals, the company said in a statement Thursday.
The company had earlier said that its vaccine was 89.3% effective in the U.K., based on an interim analysis of the study of more than 15,000 people. An interim analysis of the South Africa data had shown it was 49.4% effective overall.
Novavax Inc.'s Covid-19 vaccine was 96.4% effective against mild, moderate and severe symptoms of the disease in the final analysis of a late-stage trial in the U.K.
Shares of the drugmaker were up 16% in after-hours trading Thursday in New York. Since the start of this year, the stock had gained more than 68% through Thursday's close.
The company also released final results of a mid-stage trial from South Africa showing that its vaccine was 55.4% effective against a variant circulating there that's already been shown to partially elude the effects of some shots. Both studies reached their statistical goals, the company said in a statement Thursday.
The company had earlier said that its vaccine was 89.3% effective in the U.K., based on an interim analysis of the study of more than 15,000 people. An interim analysis of the South Africa data had shown it was 49.4% effective overall.